Gilead Sciences Inc Revenue Growth Rates (GILD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gilead Sciences Inc   (NASDAQ: GILD)
 

GILD's Revenue Growth by Quarter and Year

Gilead Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GILD/growth
https://api.csimarket.com/api/v1/companies/GILD/fundamentals
https://api.csimarket.com/api/v1/companies/GILD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GILD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8,300.00
2nd Quarter June 7,803.00
1st Quarter March 6,960.00
FY 23,063.00

GILDs Annual Revenue
Gilead Sciences Inc 's Revenue in the fiscal year 2025 $ 29,443.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2024 $ 28,754.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2023 $ 27,116.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2022 $ 27,281.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2021 $ 27,305.00 millions




GILD Revenue third quarter 2026 Y/Y Growth Comment
Gilead Sciences Inc reported Revenue growth of 6.83% year on year in the third quarter 2026, to $ 8,300.00 millions, this is lower than Gilead Sciences Inc 's recent average Revenue increase of 18.95%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue growth. While Gilead Sciences Inc ' s Revenue increase of 6.83% ranks overall at the positon no. 2115 in the third quarter 2026.


GILD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.83 %
2nd Quarter June 10.18 %
1st Quarter March 4.39 %
FY   -

Financial Statements
Gilead Sciences Inc 's third quarter 2026 Revenue $ 8,300.00 millions GILD's Income Statement
Gilead Sciences Inc 's third quarter 2025 Revenue $ 7,769.00 millions Quarterly GILD's Income Statement


GILD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.37 %
2nd Quarter June 12.11 %
1st Quarter March -12.18 %
FY (Year on Year)   -


Back to GILD Growth rate Comparisons >> Back to GILD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #313
Overall #2115

Revenue Y/Y Growth Statistics
High Average Low
136.14 % 18.95 % -21.78 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #313
Overall #2115
Revenue Y/Y Growth Statistics
High Average Low
136.14 % 18.95 % -21.78 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Gilead Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
60.23 % 4.4 % -14.47 %
(March 31, 2014)  


GILD's III. Quarter Q/Q Revenue Comment
Gilead Sciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.37%, to $ 8,300.00 millions, from $7,803.00 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Gilead Sciences Inc 's Revenue growth quarter on quarter, overall rank is 1062.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #157
Overall #1062
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #157
Overall #1062
Revenue Q/Q Growth Statistics
High Average Low
60.23 % 4.4 % -14.47 %
(March 31, 2014)  


GILD's III. Quarter Q/Q Revenue Comment
Gilead Sciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.37%, to $ 8,300.00 millions, from $7,803.00 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Gilead Sciences Inc 's Revenue growth quarter on quarter, overall rank is 1062.


Gilead Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 30,988.00
Y / Y Revenue Growth (TTM) 6.54 %
Year on Year Revenue Growth Overall Ranking # 2282
Seqeuential Revenue Change (TTM) 1.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 2282


Cumulative Revenue growth Comment
Although Gilead Sciences Inc 's Annual Revenue growth year on year were below company's average 18.15% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.54% year on year, from 5.52% in Jun 30 2026.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2282, from total ranking in previous quarter at 2716.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 336
Overall # 2351

Revenue TTM Y/Y Growth Statistics
High Average Low
122.2 %
 18.15 %
-18.91 %
IV. Quarter  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 370
S&P 500 # 2579
Cumulative Revenue growth Comment
Although Gilead Sciences Inc 's Annual Revenue growth year on year were below company's average 18.15% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.54% year on year, from 5.52% in Jun 30 2026.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2282, from total ranking in previous quarter at 2716.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 336
Overall # 2351

Revenue TTM Y/Y Growth Statistics
High Average Low
122.2 %
18.15 %
-18.91 %
IV. Quarter  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 370
S&P 500 # 2579




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GILD's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions
Warby Parker Inc 10.77%$ 10.767 millions
Cerus Corporation10.69%$ 10.690 millions
Biogen Inc 10.63%$ 10.628 millions
Chemed Corporation10.57%$ 10.568 millions
Edwards Lifesciences Corporation10.47%$ 10.471 millions
Biodesix Inc 10.44%$ 10.442 millions
Medline Inc 10.41%$ 10.415 millions
Jazz Pharmaceuticals Plc10.38%$ 10.380 millions
Abbvie Inc 10.32%$ 10.319 millions
Livanova Plc10.17%$ 10.170 millions
Kura Oncology Inc 10.07%$ 10.067 millions
Amneal Pharmaceuticals Inc 10.04%$ 10.040 millions
Quest Diagnostics Inc9.98%$ 9.979 millions
Idexx Laboratories Inc9.95%$ 9.950 millions
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions


About Gilead Sciences Inc Revenue Growth Rates (GILD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gilead Sciences Inc (CIK 882095).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000882095-26-000039
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gilead Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.